Karl E Watkin

• Led Chairman and Board-level leadership across Australian and UK pharmaceutical, bioscience, and technology businesses, enhancing strategy, governance, innovation, and long-term enterprise development. • Lead development of emerging pharmaceutical and bioscience technologies and products spanning the UK, Australia, New York, Hong Kong and Vietnam, connecting scientific innovation with commercial opportunity. • Advised on strategic partnerships and technology development, driving international business growth through extensive public-company governance and entrepreneurial experience. • Advanced bioscience initiatives, including Phenome-related research infrastructure and the deployment of bioscience solutions across UK and international markets.

• Served as Chairman with Board-level responsibility for strategic direction, governance and commercial oversight of the aviation business.
• Applied extensive entrepreneurial and international operating experience to strategic decision-making within a developing Australian enterprise.
• Provided leadership across stakeholder, commercial and governance considerations relevant to sustainable business development.
• Contributed senior Board judgment developed through four decades of company creation, transformation, investment and public-market experience.

• Provided Board leadership to an international business operating across Australian and UK markets.
• Applied corporate governance, strategic planning and entrepreneurial leadership to support business direction and stakeholder priorities.
• Leveraged extensive experience in emerging technologies, international commercialization and strategic business development.
• Supported Board-level decision-making with a focus on long-term enterprise development and commercial opportunity.

• Founded and directed a research-led technology business developing patented technology designed to mimic nature in producing active pharmaceutical and nutraceutical ingredients.
• Led commercialization and strategic development of the technology following the first patent grant in August 2017, with further intellectual-property development under way.
• Connected emerging bioscience technology with pharmaceutical, nutraceutical and commercial applications across international markets.
• Applied entrepreneurial, investment, strategic partnership and technology-development expertise to move an emerging innovation toward commercial deployment.

• Founded and developed D1 Oils, a biofuel business subsequently listed and sold to BP, demonstrating the ability to build an energy-transition enterprise from entrepreneurial concept through public markets and strategic exit.
• Established a business model focused on biofuels and sustainable energy while developing international commercial and stakeholder relationships.
• Strategy was commended internationally in New York in 2007 by Bill Clinton, Al Gore, Tony Blair, Kofi Annan and Desmond Tutu.
• The initiative created 350,000 jobs for the global rural poor, demonstrating the potential for commercially driven energy-transition activity to deliver broader economic impact.